| Abstrakt: |
A recent study conducted by researchers at the University of Campania in Naples, Italy, explores the potential of personalized medicine in the field of cardiovascular diseases. The study highlights the role of pharmacogenomics in tailoring drug therapies for patients with conditions such as atherosclerosis, thromboembolism, and dyslipidemia. The researchers emphasize the importance of genotype-guided approaches in antiplatelet therapy, anticoagulant use, and dyslipidemia treatment. They suggest that pharmacogenomics has the potential to improve patient care, reduce healthcare costs, and decrease mortality rates in cardiovascular diseases. [Extracted from the article] |
